

**Circulating Tumor Cell  $\gamma$ H2AX Immunofluorescence Assay**  
**NCI Publications**[A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas](#)

Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH. 2012. *Clinical Cancer Research* 18(6). p. 1726-34. PMID: 22307137

[Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas](#)

Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH. 2011. *Cancer Research* 71(17). p. 5626-34. PMID: 21795476

[Histone  \$\gamma\$ H2AX and poly\(ADP-ribose\) as clinical pharmacodynamic biomarkers](#)

Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH, Pommier Y. 2010. *Clinical Cancer Research* 16(18). p. 4532-42. PMID: 20823146

[Monitoring drug-induced  \$\gamma\$ H2AX as a pharmacodynamic biomarker in individual circulating tumor cells](#)

Wang L, Pfister T, Parchment RE, Kummar S, Rubinstein L, Evrard YA, Gutierrez ME, Murgo AJ, Tomaszewski JE, Doroshow JH, Kinders RJ. 2010. *Clinical Cancer Research* 16(3). p. 1073-84. PMID: 20103672

[Use of circulating tumor cells to monitor pharmacodynamic responses of patients in early stage clinical trials](#)

Kinders RJ, Wang L, Kummar S, et al. 2010. AACR Annual Meeting 2010:Abstract LB-286